Market Overview

UPDATE: Morgan Stanley Reiterates On CIGNA As 4Q Issues May Linger

Share:
Related CI
Virginia Cancer Institute and Cigna Collaborate to Improve Care for People Undergoing Cancer Treatment
CIGNA CEO Explains Why The Anthem-CIGNA Deal Won't Face Antitrust Issues
Big Health Insurers Consolidate...Should You Buy? (Seeking Alpha)

In a report published Friday, Morgan Stanley analyst Andrew Schenker reiterated an Overweight rating on CIGNA (NYSE: CI), but lowered the price target from $100.00 to $93.00.

In the report, Morgan Stanley noted, “Issues CI experienced in 4Q may spill over into 2014 results. However, >$1.5B in deployable cash in FY14 and improvements in 2H14 should yield mid single-digit EPS growth. Our adjusted EPS of $7.16 reflects 6% Y/Y growth off a lower 2013 platform.”

CIGNA closed on Friday at $76.14.

Latest Ratings for CI

DateFirmActionFromTo
Jul 2015BarclaysMaintainsEqual-weight
Jul 2015Sterne AgeeUpgradesNeutralBuy
Jul 2015SusquehannaMaintainsPositive

View More Analyst Ratings for CI
View the Latest Analyst Ratings

Posted-In: Andrew Schenker Morgan StanleyAnalyst Color Price Target Analyst Ratings

 

Related Articles (CI)

Get Benzinga's Newsletters